These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25595389)

  • 1. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice.
    Scherließ R; Mönckedieck M; Young K; Trows S; Buske S; Hook S
    Int J Pharm; 2015 Feb; 479(2):408-15. PubMed ID: 25595389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
    Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
    Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
    J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
    Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
    Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
    Hellfritzsch M; Christensen D; Foged C; Scherließ R; Thakur A
    Int J Pharm; 2023 Dec; 648():123581. PubMed ID: 37931728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.
    Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z
    J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
    Slütter B; Jiskoot W
    J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curdlan sulfate-
    Zhang S; Huang S; Lu L; Song X; Li P; Wang F
    Int J Nanomedicine; 2018; 13():2377-2394. PubMed ID: 29713168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-conjugated N-trimethylaminoethylmethacrylate chitosan nanoparticles induce strong immune responses after nasal administration.
    Liu Q; Zheng X; Zhang C; Shao X; Zhang X; Zhang Q; Jiang X
    Pharm Res; 2015 Jan; 32(1):22-36. PubMed ID: 24970313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines.
    Kobayashi T; Fukushima K; Sannan T; Saito N; Takiguchi Y; Sato Y; Hasegawa H; Ishikawa K
    Viral Immunol; 2013 Apr; 26(2):133-42. PubMed ID: 23509985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
    Gordon S; Saupe A; McBurney W; Rades T; Hook S
    J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations.
    Scherließ R; Buske S; Young K; Weber B; Rades T; Hook S
    Vaccine; 2013 Oct; 31(42):4812-9. PubMed ID: 23933339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity.
    Kalkanidis M; Pietersz GA; Xiang SD; Mottram PL; Crimeen-Irwin B; Ardipradja K; Plebanski M
    Methods; 2006 Sep; 40(1):20-9. PubMed ID: 16997710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.
    Mittal A; Schulze K; Ebensen T; Weissmann S; Hansen S; Guzmán CA; Lehr CM
    J Control Release; 2015 May; 206():140-52. PubMed ID: 25795506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
    Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
    J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.